• 1
    Mehta J,Singhal S. High-dose chemotherapy and autologous hematopoietic stem cell transplantation in myeloma patients under the age of 65 years. Bone Marrow Transplant 2007; 40: 11011114.
  • 2
    Pant S,Copelan EA. Hematopoietic stem cell transplantation in multiple myeloma. Biol Blood Marrow Transplant 2007; 13: 877885.
  • 3
    Attal M,Harousseau JL,Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996; 335: 9197.
  • 4
    Child JA,Morgan GJ,Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 18751883.
  • 5
    Palumbo A,Bringhen S,Petrucci MT, et al. Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: Results of a randomized controlled trial. Blood 2004; 104: 30523057.
  • 6
    Desikan KR,Barlogie B,Jagannath S, et al. Comparable engraftment kinetics following peripheral-blood stem-cell infusion mobilized with granulocyte colony-stimulating factor with or without cyclophosphamide in multiple myeloma. J Clin Oncol 1998; 16: 15471553.
  • 7
    Fitoussi O,Perreau V,Boiron JM, et al. A comparison of toxicity following two different doses of cyclophosphamide for mobilization of peripheral blood progenitor cells in 116 multiple myeloma patients. Bone Marrow Transplant 2001; 27: 837842.
  • 8
    Ketterer N,Salles G,Moullet I, et al. Factors associated with successful mobilization of peripheral blood progenitor cells in 200 patients with lymphoid malignancies. Br J Haematol 1998; 103: 235242.
  • 9
    Pusic I,Jiang SY,Landua S, et al. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. Biol Blood Marrow Transplant 2008; 14: 10451056.
  • 10
    Russell NH,McQuaker G,Stainer C, et al. Stem cell mobilization in lymphoproliferative diseases. Bone Marrow Transplant 1998; 22: 935940.
  • 11
    Seggewiss R,Buss EC,Herrmann D, et al. Kinetics of peripheral blood stem cell mobilization following G-CSF-supported chemotherapy. Stem Cells 2003; 21: 568574.
  • 12
    Dingli D,Nowakowski GS,Dispenzieri A, et al. Cyclophosphamide mobilization does not improve outcome in patients receiving stem cell transplantation for multiple myeloma. Clin Lymphoma Myeloma 2006; 6: 384388.
  • 13
    Copelan EA,Ceselski SK,Ezzone SA, et al. Mobilization of peripheral-blood progenitor cells with high-dose etoposide and granulocyte colony-stimulating factor in patients with breast cancer, non-Hodgkin's lymphoma, and Hodgkin's disease. J Clin Oncol 1997; 15: 759765.
  • 14
    Kanfer EJ,McGuigan D,Samson D, et al. High-dose etoposide with granulocyte colony-stimulating factor for mobilization of peripheral blood progenitor cells: Efficacy and toxicity at three dose levels. Br J Cancer 1998; 78: 928932.
  • 15
    Reiser M,Josting A,Draube A, et al. Successful peripheral blood stem cell mobilization with etoposide (VP-16) in patients with relapsed or resistant lymphoma who failed cyclophosphamide mobilization. Bone Marrow Transplant 1999; 23: 12231228.
  • 16
    Bolwell BJ,Pohlman B,Rybicki L, et al. Patients mobilizing large numbers of CD34+ cells (super mobilizers) have improved survival in autologous stem cell transplantation for lymphoid malignancies. Bone Marrow Transplant 2007; 40: 437441.
  • 17
    Chou T,Ishiguro T,Imajo K, et al. [A multicenter early phase II study of high-dose chemotherapy with autologous peripheral blood stem cell transplantation for treatment of intermediate-grade non-Hodgkin's lymphoma.Japan Blood Cell Transplantation Study Group]. Rinsho Ketsueki 1999; 40: 10581067.
  • 18
    International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: A report of the International Myeloma Working Group. Br J Haematol 2003; 121: 749757.
  • 19
    Greipp PR,San Miguel J,Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23: 34123420.
  • 20
    Avet-Loiseau H,Attal M,Moreau P, et al. Genetic abnormalities and survival in multiple myeloma: The experience of the Intergroupe Francophone du Myelome. Blood 2007; 109: 34893495.
  • 21
    Durie BG,Harousseau JL,Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 14671473.
  • 22
    Attal M,Harousseau JL,Facon T, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003; 349: 24952502.
  • 23
    Knop S,Gerecke C,Liebisch P, et al. Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: A report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom). Blood 2009; 113: 41374143.
  • 24
    Harousseau JL. Induction therapy in multiple myeloma. Hematology Am Soc Hematol Educ Prog 2008: 306312.
  • 25
    Kumar S,Giralt S,Stadtmauer EA, et al. Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens. Blood 2009; 114: 17291735.
  • 26
    Jansen J,Thompson J,Dugan M, et al. Impaired PBPC collection in patients with myeloma after high-dose melphalan. Cytotherapy 2004; 6: 498504.
  • 27
    Boccadoro M,Palumbo A,Bringhen S, et al. Oral melphalan at diagnosis hampers adequate collection of peripheral blood progenitor cells in multiple myeloma. Haematologica 2002; 87: 846850.
  • 28
    Knudsen LM,Rasmussen T,Jensen L,Johnsen HE. Reduced bone marrow stem cell pool and progenitor mobilization in multiple myeloma after melphalan treatment. Med Oncol 1999; 16: 245254.
  • 29
    Mendrone AJr,Arrais CA,Saboya R, et al. Factors affecting hematopoietic progenitor cell mobilization: An analysis of 307 patients. Transfus Apher Sci 2008; 39: 187192.
  • 30
    Tricot G,Jagannath S,Vesole D, et al. Peripheral blood stem cell transplants for multiple myeloma: Identification of favorable variables for rapid engraftment in 225 patients. Blood 1995; 85: 588596.
  • 31
    Gertz MA,Kumar SK,Lacy MQ, et al. Comparison of high-dose CY and growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple myeloma. Bone Marrow Transplant 2009; 43: 619625.
  • 32
    Martin A,Perez-Simon JA,Caballero MD, et al. Effect of cumulative etoposide doses on the outcome of autologous peripheral-blood progenitor-cell transplantation for lymphoma. Bone Marrow Transplant 2004; 33: 579587.
  • 33
    Barlogie B,Jagannath S,Vesole DH, et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 1997; 89: 789793.
  • 34
    Dewald GW,Kyle RA,Hicks GA,Greipp PR. The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia, or amyloidosis. Blood 1985; 66: 380390.